225 related articles for article (PubMed ID: 24412340)
1. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
[TBL] [Abstract][Full Text] [Related]
3. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
Müller H; Gabrielli V; Agoglitta O; Holl R
Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors.
Wimmer S; Hoff K; Martin B; Grewer M; Denni L; Lascorz Massanet R; Raimondi MV; Bülbül EF; Melesina J; Hotop SK; Haupenthal J; Rohde H; Heisig P; Hirsch AKH; Brönstrup M; Sippl W; Holl R
Bioorg Chem; 2023 Feb; 131():106331. PubMed ID: 36587505
[TBL] [Abstract][Full Text] [Related]
7. Design and stereoselective synthesis of a C-aryl furanoside as a conformationally constrained CHIR-090 analogue.
Oddo A; Holl R
Carbohydr Res; 2012 Oct; 359():59-64. PubMed ID: 22925765
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies.
Dreger A; Hoff K; Agoglitta O; Hotop SK; Brönstrup M; Heisig P; Kirchmair J; Holl R
Bioorg Chem; 2021 Feb; 107():104603. PubMed ID: 33429229
[TBL] [Abstract][Full Text] [Related]
9. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
[TBL] [Abstract][Full Text] [Related]
10. Chiral Pool Synthesis, Biological Evaluation and Molecular Docking Studies of C-Furanosidic LpxC Inhibitors.
Dreger A; Kharwb O; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
ChemMedChem; 2019 Apr; 14(8):871-886. PubMed ID: 30801965
[TBL] [Abstract][Full Text] [Related]
11. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
Pirrung MC; Tumey LN; McClerren AL; Raetz CR
J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
[TBL] [Abstract][Full Text] [Related]
14. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
[TBL] [Abstract][Full Text] [Related]
17. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Piizzi G; Parker DT; Peng Y; Dobler M; Patnaik A; Wattanasin S; Liu E; Lenoir F; Nunez J; Kerrigan J; McKenney D; Osborne C; Yu D; Lanieri L; Bojkovic J; Dzink-Fox J; Lilly MD; Sprague ER; Lu Y; Wang H; Ranjitkar S; Xie L; Wang B; Glick M; Hamann LG; Tommasi R; Yang X; Dean CR
J Med Chem; 2017 Jun; 60(12):5002-5014. PubMed ID: 28549219
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
Sharma A; Kumar V; Pratap S; Kumar P
Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
